Dive Brief:
- Stryker said Monday it has agreed to acquire ZuriMED, a company making a device to treat rotator cuff tears. The companies did not share the terms of the deal.
- Zurich, Switzerland-based ZuriMED makes a system for rotator cuff augmentation, a procedure where a patch is applied to a torn rotator cuff to support healing and prevent the tissue from re-tearing.
- Stryker expects the acquisition to strengthen its rotator cuff portfolio and support shoulder specialists in sports medicine and arthroplasty.
Dive Insight:
ZuriMED received Food and Drug Administration clearance in late 2024 for its FiberLocker system. During or after rotator cuff tendon repair, a polyester patch is applied and attached to the surrounding tissue. The implant is intended to stay in place, supporting the sutures and bone anchors from the surgery.
Rotator cuff repair is a common orthopedic surgery, but re-tear rates are estimated from 11% to 94%, with higher rates for older patients.
Rotator cuff augmentation is one of the fastest-growing areas in sports medicine, according to Stryker. Andy Pierce, Stryker’s group president of MedSurg and Neurotechnology, said in a statement that ZuriMED’s technology addresses an important clinical need within shoulder care.
The acquisition is subject to closing conditions, and ZuriMED will operate as a separate entity until the deal closes.
